Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 01:30:02 12/07/2025 am IST			After hours 05:30:00 am
83.36 ^USD	-0.79%		83.05	-0.37%

11/07	Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	RE
11/07	Global markets live: Tesla, Nvidia, Google, BP, Nissan…

BioNTech takes over CureVac in $1.25 billion all-stock deal among COVID rivals

Published on 12/06/2025 at 16:30, updated on 12/06/2025 at 19:27

This article is reserved for members

Unlock the article: REGISTER NOW!

100% Free Registration

Already a customer? Log In

Latest news about Merck & Co., Inc.

Health Rounds: Experimental Bayer drug eases menopause-like symptoms from breast cancer therapy	11/07	RE
Global markets live: Tesla, Nvidia, Google, BP, Nissan…	11/07
MERCK : Jefferies raises TP after Verona acquisition	11/07	CF
FDA May Fast Track Drug Reviews for Lower US Prices, Bloomberg Reports	11/07	MT
Wall Street Waits to Hear the Numbers	11/07
Jefferies Adjusts Merck & Co.'s Price Target to $141 From $138, Keeps Buy Rating	11/07	MT
Merck: Jefferies raises TP after Verona acquisition	11/07	CF
Merck: FDA approval for Bravecto Quantum	11/07	CF
Merck: seeks FDA approval for new HIV treatment	11/07	CF
Merck Animal Health's Flea-and-Tick Treatment Approved in U.S.	11/07	DJ
Merck Animal Health Gets FDA Approval for Bravecto Quantum	11/07	MT
Fda approves Bravecto Quantum, a long-acting injectable for dogs 6 months and older	10/07	RE
Morgan Stanley Adjusts Price Target on Merck to $98 From $99, Maintains Equalweight Rating	10/07	MT
Global markets live: Nvidia, Tesla, Blackstone, BMW, Samsung…	10/07
AI Mania Masks Trade War Risks	10/07
U.S. FDA Accepts New Drug Application for Merck's Doravirine/Islatravir, an Investigational, Once-Daily, Oral, Two-Drug Regimen for Treatment of Adults with Virologically Suppressed HIV-1 Infection	10/07	CI
Merck Says FDA Accepts for Review New Drug Application for Doravirine/Islatravir to Treat HIV-1 Infection in Adults	10/07	MT
Merck : FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection	10/07	DJ
U.S. FDA accepts new drug application for Merck's doravirine/islatravir	10/07	RE
Deals of the day-Mergers and acquisitions	10/07	RE
Formycon tops SDax with news on FYB206	10/07	DP
Merck & Co snaps up respiratory drug maker Verona for USD10 billion	10/07	AN
Severn Trent "on track"; WPP makes non-exec next CEO	10/07	AN
PRESS DIGEST-British Business - July 10	10/07	RE
Merck shells out $10 billion for Verona in bid to diversify beyond Keytruda	10/07	RE

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows: - sale of pharmaceutical products (67%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.; - sale of vaccines (22.1%); - sale of animal health products (9.4%); - other (1.5%). Net sales are distributed geographically as follows: the United States (47.4%), Europe/Middle East/Africa (22%), China (11.3%), Japan (5.3%), Asia/Pacific (5.4%), Latin America (5.1%) and other (3.5%).

Employees

74,000

Sector

Pharmaceuticals

Calendar

15/07 - International AIDS Society Conference

More about the company